At a glance
- Originator Mitsubishi Chemical
- Developer Dynogen Pharmaceuticals
- Class Analgesics; Antidepressants; Irritable bowel syndrome therapies; Nootropics; Pyrimidines; Small molecules; Urologics
- Mechanism of Action Adrenergic receptor antagonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome; Major depressive disorder; Nausea and vomiting; Overactive bladder
Most Recent Events
- 23 May 2008 Adverse events data from a Phase-IIa trial in Irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008)
- 17 Jan 2008 Patent rights and know-how relating to DDP 225 transferred from Arachnova Therapeutics to Dynogen Pharmaceuticals through an asset purchase agreement
- 20 Dec 2007 Discontinued - Phase-II for Nausea and vomiting in USA (PO)